BTAI 241220 1.00C (BTAI241220C1000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

BTAI241220C1000

Watchlist

0.04
-0.01-20.00%

15min DelayClose Nov 27 16:00 ET

0.04High0.04Low

Intraday

5D
Daily

News

12 Health Care Stocks Moving In Friday's Pre-Market Session
BenzingaNov 22 16:06 ET
Bioxcel Therapeutics Restructures Credit and Strengthens Leadership
TipRanksNov 21 17:00 ET
BioXcel Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock and Warrants
Quiver QuantitativeNov 21 16:50 ET
BioXcel Therapeutics Commences Public Offering Of Shares Of Its Common Stock And Accompanying Warrants; No Terms Disclosed
BenzingaNov 21 16:49 ET
BioXcel Therapeutics Announces Proposed Public Offering
GlobeNewswireNov 21 16:47 ET
Express News | BioXcel Therapeutics- as of Nov 18, ‘431 Patent Has Been Accepted for Listing in FDA Approved Drug Products With Therapeutic Equivalence Evaluations
ReutersNov 21 16:45 ET

Comments

Jaguar8

Nov 22 07:29

NEWS

$BioXcel Therapeutics (BTAI.US)$
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering
NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the "Company") (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the pricing of an underwritten public offering of 5,600,000 shares of its common stock, par value $0.001 per share ("Comm...

Jaguar8

Nov 12 06:01

NEWS

$BioXcel Therapeutics (BTAI.US)$
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia
First patient randomized in SERENITY At-Home trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia
Received FDA feedback on protocol for TRANQUILITY In-Care trial of BXCL501 for agitation associated with Alzheimer's dementia (AAD)
Estimated 140 ...

Trytosaveabit

Oct 15 06:21

Update!

$BioXcel Therapeutics (BTAI.US)$ BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of Bxcl501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

Jaguar8

Sep 5 06:58

NEWS

$BioXcel Therapeutics (BTAI.US)$
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

WJJG

Jul 16 06:14

Good news! 90% increase Q over Q

$BioXcel Therapeutics (BTAI.US)$ …The Company expects unaudited revenue of approximately $1.1 million for the three months ended June 30, 2024, representing an increase of approximately 90% quarter over quarter and approximately 141% compared to the same period in 2023. Revenue growth was driven by an increase in contracting with psychiatric care clinics and behavioral health facilities using a small commercial team…